Background--The progression of abdominal aortic aneurysm (AAA) involves a sustained influx of proinflammatory macrophages, which exacerbate tissue injury by releasing cytokines, chemokines, and matrix metalloproteinases. Previously, we showed that Notch deficiency reduces the development of AAA in the angiotensin II-induced mouse model by preventing infiltration of macrophages. Here, we examined whether Notch inhibition in this mouse model prevents progression of small AAA and whether these effects are associated with altered macrophage differentiation.
A dominal aortic aneurysm (AAA) is a localized dilation of the abdominal aorta exceeding the normal diameter by more than 50% of its original size. 1, 2 The prevalence of AAA ranges from 1.3% in men aged 45 to 54 years to %10% in those older than 65 years. 1, 3 Although advancements in diagnostic methods and watchful monitoring have been effective in reducing the risk of rupture, aortic aneurysms still account for more than 10 000 deaths each year in the United States alone. 1 The only treatment options for AAA are surgical or catheter-based interventions and are indicated after the aneurysm exceeds a threshold size. However, surgical interventions carry certain risks, come with an associated financial burden, and do not provide long-term survival advantage for the repair of small AAA. 4 Only with an increased understanding of the mechanisms underlying the progression of AAA will novel, nonsurgical, cost-effective therapies be devised to reduce AAA progression and rupture. [5] [6] [7] Aneurysm research using mouse models and diseased human tissues over the past 2 decades has identified the presence of mononuclear inflammatory cell infiltrate and augmented proteolytic activity as key features of AAA. [8] [9] [10] Although multiple pathogenic pathways converge to promote AAA progression, 11 the critical stimulus seems to be the differentiation of na€ ıve monocyte macrophages into the highly infiltrative M1 phenotype in response to aortic injury. 12 The sustained influx of proinflammatory M1 macrophages releases matrix metalloproteinases (MMPs) and cytokines leading to the depletion of medial smooth muscle cells. 13 Activation of MMPs also results in dissolution of the elastin and interstitial collagenous matrix of the medial layer of aorta. 8 Alternatively, macrophages also have the ability to program into the M2-phenotype, which inhibit the inflammatory response and promotes tissue repair by mechanisms dependent on transforming growth factor b2 (Tgfb2).
14 Despite major advances in our understanding of the various functions of macrophages in AAA, little is known about the regulation of macrophage differentiation and their role in AAA pathogenesis. Notch signaling is involved in multiple aspects of vascular development, smooth muscle cell proliferation, myeloid differentiation, and inflammation. [15] [16] [17] The Notch signaling pathway consists of a family of 4 Notch receptors (1 to 4) that interact with the Jagged and Delta ligand families. In the canonical signaling pathway, Notch1 is activated following receptor-ligand binding at the cell surface that induces proteolytic cleavage by several proteases, including c-secretase. 18 This cleavage results in the release and translocation of the Notch1 intracellular domain (NICD) into the nucleus, where it interacts with the transcription factor CBF-1 (also known as RBP-J or CSL) to promote transcriptional activation of downstream effectors. [18] [19] [20] Although
Notch1 is essential for embryonic survival, 21 increased expression of Notch1 is reported in thoracic aortic aneurysms and dissections, 21 AAA, [22] [23] atherosclerosis, 24 and a variety of cancers 25 and is highly associated with inflammatory macrophages. 15 Specifically, Notch1 has been suggested to regulate the expression of key inflammatory genes including Mcp1, inducible nitric oxide synthase (iNOS), Icam1, and Vcam1 in macrophages. 15, 22, 26 The proinflammatory effects of Notch1 signaling have been linked to modulation of macrophage functions, including differentiation and infiltration at the vascular injury site. [27] [28] [29] Recent publications have suggested that the Notch-RBP-J pathway controls the expression of prototypical M1 effector molecules, such as Il12 and iNOS, suggesting its role in the M1 polarization of macrophages. 22, 29, 30 However, its exact roles in M2 differentiation and functional consequences of such regulation in AAA are obscure. Our previous studies have demonstrated that Notch1 haploinsufficiency or pharmacologic inhibition prior to the development of aneurysmal dilation at days À7 and +3 of angiotensin II (AngII) infusion dramatically reduces the development of AAA in mice by preventing infiltration of macrophages at the site of vascular injury. This is associated with decreased expression of cytokines and chemokines. 22 Recent studies have substantiated our data on the protective roles for Notch1 deficiency in the development of AAA; however, its role in the progression of AAA is still speculative. 21, 23 In this study, we sought to determine the effect of pharmacological inhibition of Notch signaling (DAPT [N-(N-[3,5-difluorophenacetyl]-L-alanyl)-S-phenylglycine t-butyl ester]) on the progression of small AAA after the induction of dilation of the abdominal aorta. Our data show that pharmacological inhibition of Notch signaling in small AAA attenuates its progression by not only reducing the inflammatory response but also increasing differentiation of M2-phenotype macrophages by a Tgfb2-dependent mechanism. The abdominal aorta of Apoe À/À mice treated with DAPT also demonstrated increased contents of elastin precursors and adventitial collagen. Our findings suggest that targeting Notch signaling is a promising strategy for reducing AAA progression, particularly in those cases in which the threshold for surgical intervention for AAA has not yet been reached.
Methods Angiotensin II Infusion and DAPT Treatment
The Apoe À/À mice (8 to 10 weeks old) were randomly divided into 4 groups: Group 1 received saline for 28 days (n=6); group 2 received AngII plus vehicle for 28 days (n=12); group 3 received AngII plus DAPT (3 days after AngII infusion, n=12); and group 4 received AngII plus DAPT (8 days after AngII infusion, n=12). Mini osmotic pumps (Model 2004; Alzet) containing AngII (1000 ng/min per kilogram) or saline were implanted subcutaneously in the neck region of anesthetized mice following standard protocol. 22 Briefly, mice were anesthetized in a closed chamber with 3% isoflurane in oxygen for 2 to 5 minutes until immobile. Each mouse was then removed and taped on a heated (35 to 37°C) procedure board with 1.0% to 1.5% isoflurane administered via nose-cone during minor surgery. Mice were injected with a Notch inhibitor, DAPT (10 mg/kg dissolved in 10% ethanol, 90% corn oil; SigmaAldrich), 3 times a week subcutaneously starting 3 or 8 days after the implantation of osmotic pump and continuing until completion of the study. 31 Of note, some data from group 3 (DAPT 3 days after AngII infusion) were published in our previous study. 22 All animal experiments were approved by the institutional animal care and use committee (IACUC) at the Research Institute at Nationwide Children's Hospital.
Human Infrarenal Aortic Tissue Samples
Full-thickness aortic wall tissue specimens were collected from the infrarenal abdominal aorta from patients undergoing 
Transabdominal Ultrasound Imaging and Quantification of Aortic Width in Mice
For in vivo imaging of the abdominal aorta in mice, 2-dimensional (B-mode) ultrasound images were obtained at weekly intervals after the implantation of osmotic pumps using a VisualSonics Vevo2100 imaging system with a mechanical transducer (MS400). After 28 days, mice were deep anesthetized with ketamine (100 mg/kg) or xylazine (20 mg/kg), and the aortas were dissected and fixed in 10% formalin. Maximum aortic diameters and total lesion area were measured using a Zeis Stemi 2000-C microscope with an Axiocam MRC camera (Carl Zeiss Microscopy), as described previously. 22 The total lesion area was defined as the visible adventitial thickening in the experimental mice at day 28 of the AngII or saline infusion and was calculated using Image-Pro Plus software.
Histology, Immunohistochemistry Quantification, and Double Immunofluorescence Staining
The abdominal aortas from the mice were embedded in paraffin, and serial sections (5 lm) were obtained. Sections were stained with hematoxylin and eosin, elastin (SigmaAldrich), and collagen using standard protocol. 22 Immunohistochemistry (IHC) with antibodies for tropoelastin 34 45 and active caspase-3 46 was performed, as described previously. 22, 46, 47 The details about the antibodies are provided in Table 1 . Briefly, serial sections were deparaffinized, and antigen retrieval and blocking was performed. For IHC, the Vector ABC biotin kit and Vectastain DAB substrate (Vector Laboratories) were used for the development of reaction, and tissues were counterstained with hematoxylin. For double immunofluorescence, sections were incubated with For mRNA expression studies of the tissue, the suprarenal aorta of %5 mm was cut from experimental mice at day 28 of AngII infusion and frozen in RNAlater, and RNA was extracted using TRIzol reagent (Ambion) after homogenizing tissue with TissueLyser II (Qiagen). cDNA was synthesized using the SuperScript VILO cDNA Synthesis Kit (Invitrogen) and subjected to quantitative reverse transcriptase PCR (qRT-PCR) by SYBR Green RT-PCR kit (Applied Biosystems) using an Applied Biosystems 7500 Fast Real-Time PCR System. qRT-PCR was performed in triplicate, and fold change was determined by standardization to 18S rRNA. The expression levels were standardized against 18S rRNA using the DDCt method, and mean expression of the Apoe À/À mice with saline infusion was set to 1. The primer sequences are detailed in Table 2 .
Aortic Cell Isolation and Flow Cytometry
Aortic cells were isolated from the abdominal aorta of Apoe À/À mice at various intervals of time after AngII infusion.
Briefly, the aortas were removed from anesthetized mice (ketamine 100 mg/kg or xylazine 20 mg/kg), minced into 3-to 4-mm pieces, and placed in 1-mL digestion solution containing 0.6 U/mL Liberase Blendzyme 3 (Roche) and 50 lg/mL porcine pancreatic elastase (Sigma-Aldrich) in DMEM media. After digestion, cells were washed in fluorescence-activated cell sorting buffer (0.5% BSA and 0.02% NaN 3 in DMEM) at 300 g for 5 minutes and subjected to fluorescence-activated cell sorting after staining with total macrophage (F4/80), M1 macrophages (Il12), and M2 macrophages (Cd206), as described previously. 22 Fluorescence-activated cell sorting studies were performed on a Becton Dickinson LSRII flow cytometer with DiVa software, and data were analyzed with Flow Jo software.
Statistical Analysis
Statistical comparisons were performed using either the Student t test or 1-way ANOVA followed by the Bonferroni multiple comparison test. GraphPad Prism version 5.0 was used for these comparisons, and P<0.05 was considered significant. Assumptions of normality and equal variance were tested and satisfied using SAS software version 9.3. The Kruskal-Wallis test was performed to determine the overall significance of the data. For multiple comparisons, a postBonferroni test with Holm correction (for 3 comparisons) was performed for the ECHO data, maximal aortic width graph, and IHC quantification. For the real-time PCR quantification, we performed the Kruskal-Wallis test using a nonparametric assay for the overall significance of the data and ordinary ANOVA followed by a Bonferroni-Holm multiple comparisons test with single-pooled variance for multiple comparisons using GraphPad Prism version 5.0. For the statistical analysis of actual incidence, Fisher's exact test was used with the SAS software. The actual incidence of the disease is defined as 50% of greater increase in the maximal aortic width compared with the control group.
Results

Pharmacological Inhibition of Notch Signaling Limits the Progression of AAA in Response to AngII
We examined the therapeutic potential of Notch inhibition on the progression of small AAA in Apoe À/À mice infused with AngII using a potent Notch inhibitor (DAPT). The Apoe À/À mice were divided into the following 4 groups: group 1 received saline for 28 days (n=6); group 2 received AngII plus vehicle for 28 days (n=12); group 3 received AngII plus DAPT (3 days after AngII infusion, n=9); and group 4 received AngII plus DAPT (8 days after AngII infusion, n=12). Mice received DAPT (10 mg/kg subcutaneously) 3 times a week for 28 days. The time points were chosen to determine the effect of Notch inhibition at the key time points of AAA progression, as suggested by previous studies by us and others. 22, 53 Transabdominal ultrasound imaging ( Figure 1) performed at weekly intervals starting at day 0 showed progressive increases in luminal expansion of the abdominal aorta in Apoe À/À mice in response to AngII (group 2;
Figures 1B, 1F, 1J, 1N and 1R) compared with saline-treated Apoe À/À mice (group 1). Consistent with our previous studies and data from other groups, a significant increase in the luminal expansion of the abdominal aorta was observed as early as 7 days after treatment in response to AngII treatment in Apoe À/À mice ( Figure 1U ). 22, 53, 54 Significant decrease in the luminal expansion of the abdominal aorta was observed in Apoe À/À mice with DAPT treatment started at day 3 (group 3)
at days 14, 21, and 28 compared with group 2 ( Figure 1C , 1G, 1K, 1O, and 1S). 22 Although a marginal but insignificant increase in the luminal expansion was observed until day 14 in Apoe À/À mice treated with DAPT started 8 days after the AngII infusion (group 4), no further progression of luminal expansion was observed in this group ( Figure 1D , 1H, 1L, 1P, and 1T). The luminal expansion at day 28 was significantly less in group 4 compared with group 2 ( Figure 1U ). No significant difference in luminal expansion was observed in groups 3 and 4 compared with group 1 at any time interval ( Figure 1U ). Treatment by the Notch inhibitor did not affect survival of these mice over the 28-day course of the studies ( Figure 1V ). These findings suggest that Notch inhibition at an early stage of the disease reduced the progressive increase in luminal expansion that occurs with AngII infusion. The macroscopic examination of aortas at day 28 demonstrated a significantly increased maximal aortic width in response to AngII in group 2 (2.10AE0.22 mm; Figure 2A , 2B, 2E, and 2F) compared with saline-treated group 1 (P<0.001; 1.0AE0.03 mm). No increase in the maximal aortic width was observed in group 3 treated with DAPT started at day 3 of AngII infusion (1.16AE0.09 mm; Figure 2C , 2E, and 2F) such that aortic width was significantly less compared with group 2 (P<0.01). Marginal increase in the aortic width was observed in group 4 treated with DAPT started at day 8 of AngII infusion (1.42AE0.19 mm; Figure 2D through 2F) but was significantly less than group 2 treated with AngII alone (P<0.05). Consistent with maximal aortic width data, the total lesion area covered by the aneurysmal growth was also significantly decreased by Notch inhibitor in both these treatment groups compared with AngII alone (P<0.01; Figure 2G and architectural changes of typical AAA including thrombus formation, adventitial remodeling, inflammatory cell infiltration, and elastin fragmentation ( Figure 3B , 3F, and 3J). The aortas from group 3 treated with DAPT started at day 3 of AngII infusion displayed a well-defined lumen with no elastin fragmentation and minimal infiltration of inflammatory cells ( Figure 3C , 3G, and 3K). Despite marginal thickening in group 4, DAPT treatment started at day 8 of AngII infusion prevented disruption of the elastic lamellae, and no other characteristic features of AAA were observed in this group ( Figure 3D , 3H, and 3L). These findings suggested that Notch inhibition not only prevented the progressive growth of small AAA but also suppressed the characteristic traits of AAA. Significant increase in the mRNA expression of Notch1; its upstream ligands, Jagged1 and Dll4; and its downstream target Hey1 was observed in the aortas of group 2 mice versus group 1 ( Figure 4I through 4L). The mRNA expression of Jagged1, Dll4, and Hey1 in groups 3 and 4 decreased with DAPT treatment compared with group 2 and were comparable to group 1 ( Figure 4I through 4L). The mRNA expression of a disintegrin and metalloproteases (ADAMs) 10 and 17, which cause a proteolytic cleavage leading to the release of the intracellular domain of Notch1 (NICD), were also markedly increased in group 2 compared with group 1 and were significantly downregulated by Notch inhibition in groups 3 and 4 (P<0.01; Figure 4M and 4N). Dose-dependent decrease in Hey1 expression was also observed in the ex vivo BMM cell culture isolated from Apoe À/À mice ( Figure 4O ). The data demonstrated inhibition of several members of the Notch signaling pathway by DAPT and also suggested an active role for the Notch signaling pathway in the progression of aortic aneurysms.
DAPT Decreases the Expression of Notch
DAPT-Induced Stabilization of AAA is Associated With Increased Synthesis of Elastin Precursors
Activation of MMPs and fragmentation of elastin have been suggested as biomarkers for AAA progression.
55,56
Consequently, we evaluated whether Notch inhibition provides stability to the aneurysmal tissue by altering these characteristic features of the aneurysmal tissue. We particularly focused on the areas of marginal thickening in the abdominal aorta from DAPT-treated Apoe À/À mice for better understanding of the alterations caused by Notch inhibition with regard to AAA stability (brackets in Figure 3E through 3H). Marked fragmentation of elastic fibers was observed in AngII-treated group 2 compared with saline-treated group 1 (P<0.001; Figure 5A , 5B, and 5Y). Occasional elastin fragmentation was also observed in group 4 treated with DAPT started 8 days after the AngII infusion but was significantly less compared with group 2 ( Figure 5D and 5Y). No detectable elastin degradation was observed in group 3 treated with DAPT started 8 days after the AngII infusion ( Figure 5C and 5Y) . Quantification of the elastin fragments revealed a 3.5-fold increase in the elastin fragmentation in group 2 compared with only 1.5-fold in group 4 (P<0.05; Figure 5Y ). Elastin fibers are formed by crosslinking of the soluble protein tropoelastin, which provides architectural stability to the aorta. Negligible immunostaining of tropoelastin was observed in the saline-treated Apoe À/À mice ( Figure 5E ). A marginal but insignificant increase in tropoelastin immunostaining was observed in group 2 treated with AngII alone and group 3 treated with DAPT started 3 days after the AngII infusion ( Figure 5F and 5G). Robust increases in tropoelastin immunostaining were observed in the abdominal aorta from group 4 treated with DAPT started 8 days after the AngII infusion compared with group 2 ( Figure 5H ). The mRNA expression of tropoelastin in response to AngII increased by 6-fold in group 2 compared with group 1 (P<0.01; Figure 5Z ). A similar increase in the mRNA expression of tropoelastin was also observed in group 4 and was comparable to group 2 ( Figure 5Z ). Tropoelastin expression was also increased by %3.5-fold in group 3 compared with group 1 but was significantly less than group 2 or group 4 (P<0.05; Figure 5Z ). Hyaluronic acid is an important elastogenic factor secreted by smooth muscle cells and plays a key role in the elastic fiber assembly through binding with elastinassociated proteins including tropoelastin. Increased immunostaining of hyaluronic acid was observed in the medial aortic layer of groups 3 and 4 compared with group 2 ( Figure 5I through 5L). Increased collagen content was observed in the aortas of groups 3 and 4 compared with group 2 and was predominant in the adventitial region ( Figure 5M through 5P) . The IHC also showed increased immunostaining of type III collagen in group 4 compared with group 2 ( Figure 5U through 5X) , whereas the expression of type I collagen was similar in group 4 compared with group 2 ( Figure 5Q through 5T) . The mRNA expression of collagen I-a1 (Col1a1), collagen-a2 (Col1a2), and collagen III (Col3a1) was increased by almost 20-fold in response to AngII in group 2 compared with group 1 (Figure 5AA through 5AC) . The Col1a1, Col1a2, and Col3a1 mRNA levels were also increased of AngII. Y, Semiquantitative analysis of elastin fragmentation score using an arbitrary scale from 0 to 4, with 0 representing no visible disruption of medial elastin lamellae and 4 representing a severe transmural elastin fragmentation (details described under Methods). Total RNA were isolated from equal-length abdominal aorta and subjected to qRT-PCR. Shown in the figure (Z through AC) are qRT-PCR results using primers for tropoelastin (Eln), Col1a1, Col1a2, and Col3a1 standardized to 18S rRNA and reported as ratio (meanAESEM, n=3 for each group) to saline treated mice. Scale bar=50 lm in A through P. ***P<0.001; **P<0.01; *P<0.05. marginally in the aortas of DAPT-treated groups 3 and 4 (%4-fold) but were significantly less than in group 2 (P<0.05; Figure 5AA through 5AC). The integrity of the endothelial layer was examined in the experimental aortas by double immunostaining with PECAM and anti-a-smooth muscle actin ( Figure 6A through 6P) . A clear loss of endothelial cell layer was observed in the areas of elastin fragmentation in group 2 ( Figure 6B ). No such breaks in the endothelial cell layers were observed in group 3 or group 4, suggesting preventive effects of Notch inhibition on the loss of endothelial cell layer ( Figure 6C , 6D, 6K, and 6L). The data suggested that Notch inhibition may lead to the stabilization of the aneurysmal aorta associated with regeneration of elastin precursors and reduction in collagen degradation.
DAPT-Induced Stabilization of AAA is Associated With Decreased Proteolytic MMPs and Reduced Ratio of MMPs to Tissue Inhibitors of Metalloproteinases
Excessive MMP activation causes degradation of the elastin and interstitial collagenous matrix of the medial layer of aorta. We next examined whether the preventive effects of Notch inhibitor on AAA progression are associated with decreased MMP expression. Our data demonstrated a marked increase in the mRNA expression of Mmp2, Mmp3, Mmp9, and Mmp13 in the aorta of Apoe À/À mice in response to AngII in group 2 ( Figure 7A through 7D ). The expression of these MMPs was significantly decreased by the Notch inhibitor in groups 3 and 4 (P<0.01; Figure 7A through 7D). The balance between MMPs and their physiological inhibitors tissue inhibitors of metalloproteinases (TIMPs) determines the activity and potential of the MMPs to degrade extracellular matrix components. The Timp1 and Timp2 mRNA levels were increased by 20-and 4-fold, respectively, in group 2 compared with group 1 ( Figure 7E and 7F), whereas expression of Timp1 and Timp2 in groups 3 and 4 increased only %2-fold compared with group 1 and were significantly lower than group 2 (P<0.05). The expression of Timp3 was moderately increased by AngII infusion and was comparable among groups 2, 3, and 4 ( Figure 7G ), such that the relative ratios of Mmp2 to Timp3 and Mmp9 to Timp3 were significantly lower in DAPT-treated groups 3 and 4 compared with group 2 (P<0.05; Figure 7H and 7I). Protein expression of Mmp2 and Mmp9 was also decreased significantly by Notch inhibitor in these experimental animals, as determined by IHC followed by semiquantitative analysis of the adventitial layer of aorta ( Figure 7J through 7S) . The data demonstrated a robust increase in the proteolytic MMPs and imbalance in the MMPto-TIMP ratio in the macrophage-rich adventitial layer of the abdominal aorta in a mouse model of AngII and its subsequent reduction by Notch inhibition. Studies have shown that disruption of the Notch signaling pathway by gene deletion or c-secretase inhibitor induces mucosecreting goblet cell conversion of crypt proliferative cells in the intestine. 57 Indeed, we detected increases in the size and number of goblet cells in the crypts of intestinal tissue in DAPT-treated Apoe À/À mice ( Figure 8A through 8H) . Previously, we also demonstrated that deficiency of Notch1 promotes calcification in an in vitro primary aortic valve cell culture system. 51, 52 No changes in the calcium contents of aortic tissue were observed in these experimental groups in response to DAPT, suggesting that these effects of Notch1 signaling on calcification may be cell dependent ( Figure 8I through 8P).
Notch Inhibition Decreases M1-Differentiated Macrophages and Increases M2-Differentiated Macrophages in the Abdominal Aorta of Apoe
À/À
Mice in Response to AngII
Macrophage infiltration in response to AngII is an important step in AAA formation and progression in the AngII mouse model of AAA. First, we examined whether progression of AAA in Apoe À/À mice in response to AngII is accompanied by alterations in the M1 or M2 differentiation of na€ ıve macrophages and their preferential influx. Flow cytometry (fluorescence-activated cell sorting) was performed on aortic cell suspensions in the abdominal aorta of Apoe À/À mice infused with AngII at various time intervals (days 0, 3, 7, 14, 21, and 28) using F4/80, Il12, and Cd206 surface markers to highlight total and M1-and M2-differentiated macrophages, respectively. In untreated Apoe À/À mice, total macrophages (stained with F4/80) contributed to less than 10% of the total aortic cell population and were primarily negative Figure 9A and 9B) . In response to AngII, the total population of macrophages increased to 27% of all aortic cells within 3 days, peaked at %40% at day 7, and remained constant thereafter until completion of the study ( Figure 9A ). The majority of infiltrated macrophages in response to AngII were positive for Il12 staining (%30%), suggesting their M1 differentiation (P<0.001; Figure 9B ). In contrast, the Cd206-positive M2 macrophages decreased from 10% in the abdominal aortas of untreated Apoe À/À mice to %2% within 3 days of AngII treatment ( Figure 9B ). This resulted in an increased ratio of M1 to M2 macrophages in response to AngII in these mice (P<0.01). Thus, the data suggested that the infiltration of M1-differentiated macrophages likely occurs at early stages of AAA development at the expense of M2 macrophages. Previously, we documented the in vitro roles for Notch1 haploinsufficiency in promoting the M2 phenotype of macrophages. 22 In this study, we determined whether pharmacological inhibition of Notch can alter the differentiation of macrophages in a mouse model of AAA after the disease is established. The sections from abdominal aorta were stained with CD68 and Mcp1 to examine the total macrophage content and their inflammatory component in response to AngII. IHC demonstrated a robust increase in CD68 staining in the aortas of AngII-treated group 2, compared with saline-treated group 1, that was primarily localized in the adventitial layer and was highly associated with Mcp1 immunostaining ( Figure 10A , 10B, 10E, and 10F). Marginal Cd68 staining was also observed in group 4 treated with DAPT started day 8 of AngII infusion but was considerably less than group 2 ( Figure 10D and 10Q) . Interestingly, the marginal increase in CD68 content in the DAPT-treated Apoe À/À mice in the adventitial region was not associated with Mcp1 expression (Figure 10H and 10R) . No increase in CD68 or Mcp1 content was observed in group 3 treated with DAPT started day 3 of AngII infusion ( Figure 10C , 10G, 10Q, and 10R). To examine whether the preventive effects of Notch inhibitor on AAA progression are associated with changes in M1 or M2 macrophages, we subjected abdominal aortic tissue from our experimental mice for immunostaining using Il12 to stain M1 macrophages and Cd206 to identify M2 macrophages. As shown in Figure 10I through 10L, significantly increased Il12 staining was observed in the adventitial region of the abdominal aorta in response to AngII in group 2 and was markedly reduced by Notch inhibitor in groups 3 and 4 ( Figure 10S ). In contrast, significantly increased Cd206 staining was observed in the adventitial region of the abdominal aorta in group 4 treated with DAPT started day 8 of AngII infusion compared with group 2 treated with AngII alone ( Figure 10M through 10P, and 10T). No differences in Il12 or Cd206 staining were observed in groups 1 and 3, likely due to a lack of macrophages ( Figure 10I , 10K, 10M, 10O, 10S, and 10T). Furthermore, staining with active caspase-3 revealed increased apoptosis in the medial and adventitial layer of group 2 ( Figure 11A through 11D) . Marginal active caspase-3 staining was observed in the medial layer of aortas with DAPT treatment in groups 3 and 4. Marginal active caspase-3 staining was observed in the macrophage-containing adventitial layer in group 4, as validated by double immunostaining showing the coexpression of active caspase-3 staining in the CD68-positive macrophages in group 4 (arrow heads in Figure 11P ). Interestingly, active caspase-3 staining in the adventitial layer of group 2 was not highly coexpressed with CD68-positive macrophages (arrow heads in Figure 11N ) and was primarily concentrated in the smooth muscle cell-rich medial layer. The data suggested that Notch inhibition is associated with decreased M1 macrophages and increased M2 macrophages at the site of vascular injury and indicated that M2 differentiation of macrophages may render them incompetent to infiltrate and participate in the propagation of inflammation. The data also demonstrated an overall imbalance of the M1-to-M2 ratio in the mouse model of AAA.
Notch Activation in Human AAA Correlates Strongly With M1-Differentiated Macrophages
Next, we examined whether human AAA is also associated with a similar predominance of M1 macrophages in the abdominal aorta ( Figure 12A through 12L) . Double immunofluorescence staining with a standard marker for M1 macrophages (IL12) and active Notch1 signaling (NICD) demonstrated negligible staining for IL12-positive macrophages or NICD in the abdominal aortas obtained from control subjects ( Figure 12A, 12D, and 12G) . The immunostaining of IL12-positive macrophages was substantially stronger in the infrarenal aortas from AAA patients ( Figure 12B and 12C ) and was found to be coexpressed with active Notch1 signaling ( Figure 12E, 12F, 12H, and 12I) . Consequently, the data demonstrated increased content of M1 macrophages in the human AAA, suggesting a close association between active Notch1 signaling and M1 polarization of macrophages.
Notch1 Deficiency Promotes M2 Differentiation by Upregulating Tgfb2 Signaling in the Macrophages and Aortas of Apoe À/À Mice in Response to AngII
To identify the potential pathways by which Notch signaling regulates macrophage differentiation in AAA, we performed an unbiased screen of cytokines and chemokines using the RT² Profiler PCR Array in primary macrophages ( Figure 13 ). The mRNA expression of M1-promoting factors was comparable in macrophages from Notch1 +/À ;Apoe À/À and Apoe À/À mice at basal levels. LPS/IFN-c increased the mRNA expression of several factors involved in the M1 polarization of macrophages including macrophage migration inhibitory factor, Il1a, Il12a, Il12b, Il15, Cxcl10, Ccl2, and Ccl12 in Apoe À/À mice and Notch1 +/À ;Apoe À/À mice compared to basal levels (Figure 13) . However, the mRNA levels of macrophage migration inhibitory factor, tumor necrosis factor-a, Il12b, Il18, Ifna2, and Ifn-c were significantly lower in Notch1 +/À ;Apoe À/À mice compared with Apoe À/À mice, suggesting differential effects of Notch1 haploinsufficiency on macrophage polarization (Figure 13) . At basal levels, significantly higher mRNA expressions of M2-differentiation-promoting factors including Tgfb2 (P<0.05), Ccxl12 (P<0.0001), Il5 (P<0.01) and Il11 (P<0.05) were observed in the BMMs isolated from Notch1 +/À ;Apoe mice compared with Apoe À/À mice ( Figure 14A ). In response to Il4, which promotes M2differentiation, Notch1 haploinsufficiency demonstrated similar upregulation of this panel of cytokines (P<0.01; Figure 14B ). The changes in mRNA expression of these cytokines (Tgfb2, Cxcl12, Il5, and Il11) were confirmed with qRT-PCR using specific primers (data not shown). Interestingly, the mRNA expression of Tgfb2 (P<0.001) and Il11 (P<0.001) was also significantly higher in the aortas from Our in vitro data suggested crosstalk between Notch1 and Tgfb2 signaling, which might mediate the upregulation of M2 differentiation of macrophages in the setting of AAA. We examined whether Tgfb2 signaling was altered by DAPT in this AAA mouse model. No visible differences in the immunostaining of Tgfb2 were observed in group 2 in response to AngII, and results were similar to saline-treated Apoe À/À mice in group 1 ( Figure 14D , 14E, and 14L). Increased immunoreactivity of Tgfb2 was observed in the macrophage-rich adventitial layer of abdominal aortas of DAPT-treated groups 3 and 4 compared with group 2 ( Figure 14F , 14G, and 14L). The immunostaining of pSmad2, a downstream effector of Tgfb2 signaling, was also increased in the adventitial layer of the abdominal aorta by Notch inhibitor in groups 3 and 4 compared with group 2 ( Figure 14H through 14K, and 14M). In the BMMs isolated from Apoe À/À mice, recombinant Tgfb2 increased the expression of Arg1, an M2-differentiation marker in the presence of IL4, whereas expression of iNos, an M1 differentiation marker, was decreased in the presence of LPS/ IFN-c ( Figure 14N and 14O) . In contrast, the Tgfb receptor kinase inhibitor (SB-431542) decreased the expression of Arg1 in response to IL4 while increasing the expression of iNos in the presence of LPS/IFN-c, suggesting that Tgfb2 mediates M2 activation of macrophages ( Figure 14L and 14M) . The data suggest that Tgfb2 is a key player to promote the differentiation of macrophages toward the M2 phenotype and may act downstream of Notch signaling in the stabilization of AAA.
Discussion
We previously reported that Notch1 haploinsufficiency and pharmacological inhibition protects against the formation of AAA in a mouse model by preventing the infiltration of proinflammatory macrophages at the site of vascular lesion. In this research, we studied whether Notch inhibitor is effective in stabilizing the progression of small AAA and explored the mechanism of the preventive effects of Notch inhibitor in the AngII-induced mouse model of AAA. Our study showed that treatment of small AAA with a potent pharmacological Notch inhibitor (DAPT) resulted in the reduction of progressive luminal expansion along with regeneration of tropoelastin and increased adventitial collagen content, which provides stability to the aorta. In addition, DAPT-treated mice also had decreased content of MMPs in the abdominal aorta, maintained lower Mmp2 to Timp3 and Mmp9 to Timp3 ratios and had less extracellular matrix degradation. Excessive differentiation of na€ ıve macrophages to the M1 phenotype occurs in a mouse model of AngII-induced AAA and may contribute to pathogenesis of disease progression. Notch1 deficiency, in contrast, is associated with upregulation of cytokines and chemokines, which promote M2 differentiation of macrophages in addition to downregulation of cytokines and chemokines, which promote M1 differentiation of macrophages. We also showed that DAPT-induced stabilization of AAA progression was associated with decreased infiltration of proinflammatory M1 macrophages and increased content of immunosuppressive M2 macrophages in the aneurysmal tissue. Finally, the data provided evidence that Notch inhibition in an AAA mouse model is associated with increased Tgfb2 signaling, which may promote M2 differentiation of na€ ıve macrophages and initiate the repair process of abdominal aorta. These data suggest that treatment with pharmacological inhibitor of Notch signaling may be a potentially promising strategy for slowing aneurysm progression.
The elastin fragmentation and collagen degradation in the medial and adventitial layers of the aorta are expected to lead to aortic dilatation and rupture, whereas prevention of such dissolution will provide stability to the tissue. 58 Our data showed that pharmacological inhibition of Notch signaling was associated with regeneration of elastin precursors including tropoelastin and hyaluronic acid; however, it has yet to be determined if these precursors mature into elastin by crosslinking. It will also be interesting to determine whether an increase in tropoelastin in response to Notch inhibition observed in our study occurred secondarily to the reduction of the inflammatory milieu or was directly regulated by Notch signaling. The altered contents of the collagens and elastin precursors can result either from decreased synthesis or excessive breakdown. 59 Increased adventitial collagen content without substantial increase in the mRNA expression of collagen by DAPT suggests that Notch inhibitor prevents the degradation of collagens and elastins and is associated with marked improvements in the architecture of the aneurysmal tissue. Given these data, the stabilization of AAA by a Notch inhibitor might be mediated not only by inhibition of macrophage infiltration but also by regeneration of elastin and prevention of elastin and collagen degradation. Excessive MMP activation causes dissolution of the elastin and interstitial collagenous matrix of the medial layer of aorta. 60, 61 Studies have shown that MMP9 expression correlates with increasing aneurysm diameter 60, 62 and MMP2 levels are elevated in the vasculature from the human aneurysm wall. 63 Consistent with other studies, 23 our data also demonstrated significant decreases in gene expression and protein content of Mmp2 and Mmp9 by Notch inhibition in the aortas of Apoe À/À mice in response to AngII. TIMPs have been found to exhibit several biochemical and physiological functions, including inhibition of pro-MMP activation and active MMPs and the induction of apoptosis. The roles of Timp1 and Timp2 in AAA seem to be controversial because targeted deletion of Timp2 resulted in attenuation of aneurysm development, presumably through its role as a cofactor in the activation of Mmp2. 64 In contrast, the role of Timp3 remains more consistent in AAA; infusion of AngII in Timp3 À/À mice led to adverse remodeling of the abdominal aorta. 65 In our studies, Notch inhibition maintained optimal ratios of Mmp2 to Timp3 and Mmp9 to Timp3, preventing degradation of the abdominal aorta by the proteolytic activity of the MMPs. A typical response to aortic injury elicits differentiation of macrophages to a classic M1 form, which produces high levels of proinflammatory cytokines and chemokines to phagocytize apoptotic cells and damage-associated debris. However, their uncontrolled production instigates inflammation and delivers proteolytic enzymes that digest extracellular matrix and render AAA unstable and progressive, associated with high levels of Il12 and iNos production. 66 Macrophages can alternatively be programmed to an immunomodulatory M2 phenotype, which counteracts the effects of M1 macrophages and dampens the inflammatory response through low Il12 and high Tgfb2 expression profiles. 67 M2 macrophages also promote tissue repair and healing through Tgfb2-dependent production of collagen and elastin precursors. 68, 69 Our data demonstrated that under aneurysmal conditions, the delicate balance between M1 and M2 macrophages is disrupted, leading to infiltration of proinflammatory M1 macrophages at the vascular injury site and simultaneous decrease in M2-differentiated macrophages. In contrast, Notch inhibition reverses the differentiation of macrophages by increasing Cd206-positive M2 macrophages in the aorta with concomitant decrease in the Il12-positive M1 macrophages. The mechanism by which Notch deficiency promotes differentiation of macrophages into the M2 phenotype is not fully understood, but our data suggest activation of the Tgfb2 signaling pathway downstream of Notch1 signaling. The critical role of Tgf-b signaling in inflammation was identified by the finding that deletion of the Tgf-br2 leads to a lethal inflammatory disorder that was transferable through bone marrow transplantation. 70 Studies also suggest that Tgfb2 activity is required for protection against the development and dissection of AAA in C57BL/6 mice treated with AngII. 71 Our observations suggest that Notch1 deficiency upregulates the expression of Tgfb2 in the differentiation of macrophages into the M2 phenotype. We also demonstrated that Notch inhibitor upregulates the Tgfb2 signaling pathway in an AAA mouse model. Although potential interactions between Notch1 and Tgfb2 have been posited, whether Notch1 and Tgfb2 act independently or cooperatively remains undefined. 72 Increased expressions of Cxcl12, Il5, Il10, and Il11 also predispose macrophages to M2 differentiation and have been shown to be downstream of Tgf-b signaling. [73] [74] [75] These data suggest that Notch1 deficiency might promote M2 differentiation of macrophages via direct upregulation of Tgfb2 expression. Several anti-inflammatory and/or anti-MMP drugs have been shown to be modestly effective in decreasing the formation of AAA in animal models. 76 However, approaches to limit progression of small AAA have not been successful, in part, because the signaling pathways involved in the disease progression may be different from the pathways implicated in the formation of the disease, making it challenging to find the key regulators of disease progression. [76] [77] [78] Due to the close association between Notch signaling and differentiation of macrophages in AAA, it is possible that Notch inhibition may provide stability to AAA by interfering at multiple levels in the pathways implicated in the progression of AAA ( Figure 15 ). Our data suggest that Notch inhibition stabilizes the progression of AAA by reducing macrophage infiltration, preventing elastin degradation, and promoting the regeneration of elastin precursors. The protective effects of Notch inhibition on AAA progression seem to be mediated by regulatory effects of Notch on macrophage differentiation. These studies also suggest that walls of established AAA still have the potential to regenerate newly synthesized elastin through pharmacological inhibition of Notch and potentially induce regression of AAA. Because drug-based therapy for AAA does not yet exist, targeting the modulation of the M2 phenotype of macrophages is an attractive approach. Identification of key molecular targets that drive M2 differentiation could lead to novel pharmacological strategies to combat other chronic inflammatory conditions. 
